SPRB Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.90%

Insider Buying (Last 12 Months): $4,584.96

Insider Selling (Last 12 Months): $4,918.98

Spruce Biosciences Insider Trading History Chart

Spruce Biosciences Share Price & Price History

^$90.44

▲ +0.28 (0.31%)

As of 12/4/2025 05:00 PM ET

Days: 30 | 90 | 365

Spruce Biosciences Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/6/2025	Parkman Healthcare Partners Ll	Major Shareholder	Buy	256	$17.91	$4,584.96	1,307
10/6/2025	Parkman Healthcare Partners Ll	Major Shareholder	Sell	257	$19.14	$4,918.98	1,050
3/20/2024	Holdings A/S Novo	Major Shareholder	Sell	4,799	$54.75	$262,745.25	40,200
3/18/2024	Holdings A/S Novo	Major Shareholder	Sell	11,226	$57.75	$648,301.50	52,906
3/14/2024	Holdings A/S Novo	Major Shareholder	Sell	25,497	$66.75	$1,701,924.75	64,133

SEC Filings (Institutional Ownership Changes) for Spruce Biosciences (NASDAQ:SPRB)

91.71% of Spruce Biosciences stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Spruce Biosciences Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2025	Cable Car Capital LP	26,666	$0.24M	0.1%	N/A	5.333%
11/7/2025	Carlyle Group Inc.	2,896,518	$24.77M	0.6%	N/A	579.304%
2/14/2025	Boothbay Fund Management LLC	288,800	$0.12M	0.0%	N/A	0.699%
2/13/2025	Renaissance Technologies LLC	405,900	$0.17M	0.0%	-33.4%	0.983%
8/16/2024	Almitas Capital LLC	396,506	$0.21M	0.1%	N/A	0.964%
8/9/2024	Renaissance Technologies LLC	366,100	$0.19M	0.0%	+35.1%	0.890%
8/6/2024	Acadian Asset Management LLC	1,367,997	$0.71M	0.0%	+270.9%	3.324%
5/16/2024	AWM Investment Company Inc.	200,000	$0.16M	0.0%	N/A	0.486%
5/10/2024	Acadian Asset Management LLC	368,831	$0.29M	0.0%	N/A	0.896%
4/25/2024	Rosalind Advisors Inc.	1,508,419	$1.19M	1.1%	-4.9%	3.666%
2/14/2024	Superstring Capital Management LP	118,814	$0.35M	0.2%	N/A	0.292%
2/13/2024	Armistice Capital LLC	2,230,000	$6.53M	0.1%	-27.0%	5.478%
2/12/2024	AIGH Capital Management LLC	2,123,863	$6.22M	2.5%	+75.4%	5.217%
2/9/2024	Worth Venture Partners LLC	526,933	$1.54M	0.8%	+74.4%	1.294%
11/15/2023	Worth Venture Partners LLC	302,074	$0.68M	0.4%	+8.8%	0.742%
11/15/2023	Armistice Capital LLC	3,056,000	$6.91M	0.1%	-12.6%	7.507%
11/13/2023	AIGH Capital Management LLC	1,211,000	$2.74M	1.3%	+9.0%	2.975%
7/26/2023	Privium Fund Management B.V.	24,554	$52K	0.0%	N/A	0.062%
5/15/2023	AIGH Capital Management LLC	1,104,000	$2.37M	0.9%	N/A	2.778%
5/5/2023	Carlyle Group Inc.	2,896,518	$6.40M	0.2%	N/A	7.287%
5/3/2023	Privium Fund Management UK Ltd	24,554	$53K	0.0%	-51.3%	0.062%
5/1/2023	Virtu Financial LLC	13,722	$30K	0.0%	N/A	0.035%
5/1/2023	Marquette Asset Management LLC	55,757	$0.12M	0.0%	-18.4%	0.140%
4/27/2023	RiverVest Venture Management LLC	2,936,281	$6.49M	7.5%	+36.7%	7.387%
2/13/2023	BML Capital Management LLC	221,830	$0.24M	0.2%	N/A	0.942%
2/9/2023	Privium Fund Management UK Ltd	50,400	$55K	0.0%	N/A	0.214%
1/12/2023	Marquette Asset Management LLC	68,357	$75K	0.0%	+6.7%	0.290%
11/14/2022	Ergoteles LLC	23,032	$32K	0.0%	-45.0%	0.098%
11/10/2022	Abingworth LLP	1,792,518	$2.47M	0.8%	N/A	7.608%
10/18/2022	Bailard Inc.	21,166	$29K	0.0%	N/A	0.090%
7/15/2022	Marquette Asset Management LLC	64,090	$0.11M	0.0%	+56.9%	0.273%
2/10/2022	Acadian Asset Management LLC	71,756	$0.32M	0.0%	N/A	0.306%
1/19/2022	Marquette Asset Management LLC	40,853	$0.18M	0.0%	N/A	0.174%
11/16/2021	Laurion Capital Management LP	11,337	$68K	0.0%	-24.2%	0.048%
11/15/2021	Deerfield Management Company L.P. Series C	2,200,000	$13.22M	0.3%	+7.5%	9.411%
11/15/2021	Rock Springs Capital Management LP	1,617,601	$9.72M	0.2%	+0.8%	6.919%
11/15/2021	Caas Capital Management LP	27,546	$0.17M	0.0%	-70.2%	0.118%
11/12/2021	Trexquant Investment LP	11,998	$72K	0.0%	N/A	0.051%
11/10/2021	Granite Point Capital Management L.P.	63,614	$0.38M	0.0%	-36.4%	0.272%
11/8/2021	State Board of Administration of Florida Retirement System	17,440	$0.11M	0.0%	N/A	0.075%
11/4/2021	Sands Capital Ventures LLC	787,007	$4.73M	0.7%	N/A	3.366%
8/16/2021	California State Teachers Retirement System	12,006	$0.14M	0.0%	+14.0%	0.051%
8/16/2021	Goldman Sachs Group Inc.	10,770	$0.12M	0.0%	-13.5%	0.046%

Data available starting January 2016

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Today's Range

Now: $90.44

$83.00

$92.40

50 Day Range

MA: $109.98

$7.81

$182.60

52 Week Range

Now: $90.44

$4.28

$240.00

Volume

47,664 shs

Average Volume

184,366 shs

Market Capitalization

$96.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.45

Who are the company insiders with the largest holdings of Spruce Biosciences?: Spruce Biosciences' top insider investors include:
Holdings A/S Novo (Major Shareholder)
Parkman Healthcare Partners Ll (Major Shareholder)
Learn More about top insider investors at Spruce Biosciences.
Who are the major institutional investors of Spruce Biosciences?: Spruce Biosciences' top institutional shareholders include:
Carlyle Group Inc. — 579.30%
Cable Car Capital LP — 5.33%
Learn More about top institutional investors of Spruce Biosciences stock.
Which institutional investors are buying Spruce Biosciences stock?: During the previous quarter, SPRB stock was bought by institutional investors including:
Carlyle Group Inc.
Cable Car Capital LP